T. Rowe Price Associates
CADL icon

T. Rowe Price Associates’s Candel Therapeutics CADL Stock Holding History

T. Rowe Price Associates’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$148K Buy
30,110
+4,296
+17% +$23.4K ﹤0.01% 2916
2025
Q4 		$146K Buy
25,814
+6,176
+31% +$33.2K ﹤0.01% 2887
2025
Q3 		$101K Hold
19,638
– – ﹤0.01% 2922
2025
Q2 		$100K Buy
19,638
+7,363
+60% +$37.9K ﹤0.01% 2891
2025
Q1 		$70K Buy
+12,275
New +$100K ﹤0.01% 2885

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's CADL Position: Q1 2026 in Review

T. Rowe Price Associates increased its Candel Therapeutics (CADL) stake by 17% in Q1 2026, buying an estimated $23.4K and bringing the position to 30,110 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #2916.

T. Rowe Price Associates first reported a position in CADL in Q1 2025 and has held it in 5 quarters since. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • T. Rowe Price Associates held 30,110 shares of Candel Therapeutics worth $148K as of Q1 2026.
  • T. Rowe Price Associates bought 4,296 Candel Therapeutics shares in Q1 2026, an estimated $23.4K.
  • Candel Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2916 holding.
  • T. Rowe Price Associates first reported a position in Candel Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.